Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Level 2 looks good.
All of Tranzyme's product candidates have been discovered using its proprietary drug discovery (chemistry) technology, MATCH
You can see how much they're actually addressing this Discovery. http://missionir.com/blog/bio-conference/tranzyme-pharma-inc-tzym-starts-presentation-at-15th-annual-bio-ceo-investor-conference/
After our there was 96,000 Thousand shares on the Bid for two hours .54 It must be bad news ha ha Ha ha ha!
I agree!
Speakers
Constrained Peptides and Macrocyclics Drug Discovery
Steven Ballet, Ph.D., Research Group of Organic Chemistry, Departments of Bio-Engineering Sciences and Chemistry, Vrije Universiteit Brussel
Christophe Bonny, Ph.D., CSO, Bicycle Therapeutics Limited
Julio Camarero, Ph.D., Associate Professor, Pharmacology and Chemistry, University of Southern California
Jennifer Cochran, Ph.D., Associate Professor, Bioengineering, Stanford University
Sarah #$%$, Ph.D., Senior Scientist II, Chemistry Department, Affymax, Inc.
Ian Lewis, Ph.D., Research Chemist, Global Discovery Chemistry, Novartis
Daniel Obrecht, Ph.D., CSO, Polyphor, Ltd.
Dinesh Patel, Ph.D., CEO, Protagonist Therapeutics
Tomi Sawyer, Ph.D., CSO, Aileron Therapeutics
Jack W. Szostak, Ph.D., Investigator, Howard Hughes Medical Institute; Professor of Genetics, Harvard Medical School; Nobel Laureate
Nick Terrett, Ph.D., CSO, Ensemble Therapeutics Corp.
Helmut Thomas, Ph.D., Senior Vice President, Research and Pre-Clinical Development, Tranzyme Pharma
Douglas A. Treco, Ph.D., President and CEO, Ra Pharmaceuticals
Christoph Zapf, Ph.D., Principal Scientist, Worldwide Medicinal Chemistry, Pfizer
Constrained Peptides and Macrocyclics Drug Discovery
Novel Peptide Therapeutics
April 16-17, 2013
Macrocyclic-Based Drug Candidates
1:25 Chairperson’s Remarks
Julio Camarero, Ph.D., Associate Professor, Pharmacology and Chemistry, University of Southern California
1:30 SOM230: A New Therapeutic Modality for Cushing’s Disease
Ian Lewis, Ph.D., Research Chemist, Global Discovery Chemistry, Novartis
SOM230 has recently shown promise as the first effective pituitary directed medical treatment for Cushing’s disease. Indeed, the multiple high affinity binding of SOM230 to somatostatin receptor subtypes enables much more effective inhibition of ACTH release in vitro and in vivo. Recent clinical studies involving treatment of Cushing’s disease with SOM230 have demonstrated that SOM230 produced a decrease in urinary free cortisol (UFC) levels in 76% of patients during 15 days, with direct effects on ACTH release, establishing a new therapeutic modality for Cushing’s disease.
2:00 Discovery of Stereochemically Complex Macrocyclic Hsp90 Inhibitors
Christoph Zapf, Ph.D., Principal Scientist, Worldwide Medicinal Chemistry, Pfizer
We wish to disclose the design and synthesis of a series of stereochemically complex, rule-of-five compliant small molecule macrocycles that were fine-tuned to be metabolically stable and devoid of hERG activity. The compounds showed impressive biomarker activity 24 hours post dosing in different cell lines. When studied in a lung cancer xenograft model, the macrocycles demonstrated prolonged exposure in tumors and significant tumor size reduction.
2:30 Discovery of TZP-102, a Macrocycle-Based Oral Ghrelin Receptor Agonist and GI Prokinetic Agent for the Treatment of Diabetic Gastroparesis
Helmut Thomas, Ph.D., Senior Vice President, Research and Preclinical Development, Tranzyme Pharma
3:00 Sponsored Presentation (Opportunity Available)
3:15 Refreshment Break in the Exhibit Hall with Poster Viewing
4:00 Macrocycles for Drug Discovery - Identification of Small Molecule Synthetic Macrocycle Antagonists of Human IL17A
Nick Terrett, Ph.D., CSO, Ensemble Therapeutics Corp.
Ensemble Therapeutics has developed a DNA-programmed chemistry platform for the rapid synthesis and screening of macrocycles (EnsemblinsTM). Using this platform, small molecule macrocyclic compounds have been discovered that are nanomolar inhibitors of the interaction of the IL17A cytokine with its receptor. These compounds are anti-inflammatory in IL17-dependent animal inflammatory models and optimized for oral bioavailability
http://www.drugdiscoverychemistry.com/Constrained-Peptide-Therapeutics/
Business Relationships
• In December 2009, Tranzyme entered into a collaboration agreement with BMS to discover, develop and commercialize novel macrocyclic compounds directed against targets of interest to BMS. Under the terms of the agreement, Tranzyme is primarily responsible for early lead discovery. BMS is solely responsible for completing preclinical and clinical development of all products arising from the collaboration, and for their commercialization globally. Tranzyme received an upfront payment of $10 million and total milestone payments under the agreement, excluding royalties, could reach up to approximately $80 million for each target program.
• In June 2010, Tranzyme entered into a license agreement with Norgine that provides Norgine with exclusive rights to develop and commercialize injectable formulations of ulimorelin (TZP-101) in Europe, Australia, New Zealand, Middle East, North Africa and South Africa. Tranzyme retains all other territories, including North America, South America and all of Asia. Norgine paid an upfront license fee of $8 million, purchased $2 million in equity upon executing the license, and is required to pay up to approximately $150 million in milestones as well as royaltiesWe are also looking to further develop our new pipeline products such as CAMETOR® for the treatment of obesity and TZP101 licensed in from Tranzyme.. Hit this link, http://www.norgine.com/pages/about_norgine/norgine_today.html
stock's been holding on pretty much here it has strength to go forward looks like! No one wants to sell down this way insiders are holding institutions are holding plus I agree with your post It's time for the stock to move back up and I believe we're very close to it now proprietary MATCH™ technology is Going to be a winner for TRANZYME! "There is no doubt that within the last 3-4 years it has been a lot easier to get pharma's attention from a collaboration standpoint," said Tranzyme Inc. VP of IP and operations Mark Peterson. Tranzyme partnered its macrocycle discovery platform with Bristol-Myers Squibb Co. in 2009.
Indeed, collaboration looks to be essential to solving the puzzle of cell access. At this point, all the lead programs disclosed thus far are aiming at extracellular targets!
tony.margani • 13 minutes ago
Very interesting read on TRANZYME
New synthesis and screening technologies and the allure of access to previously undruggable targets are driving an explosion of new company formation and deal-making around macrocycles and constrained peptides.
While it remains to be seen whether the in vitro promise of these platforms will translate into viable drug candidates, the clinical successes of macrocyclic natural products provide tantalizing hints of what could be achieved by the systematic exploration of this compound class.
Macrocycles may be capable of hitting new classes of targets because their ring structure causes them to behave differently than most small molecules.
Macrocycles are chemically defined by a ring structure of at least 12 atoms. They are typically 500-2,000 daltons in size. In contrast, most small molecules weigh less than 500 daltons, which has been considered the upper limit for a compound to be cell permeable and orally bioavailable.
"The easy targets have now been done; enzymes and GPCRs largely have been addressed through small molecules," said Ensemble Therapeutics Corp. CSO Nick Terrett. "Protein-protein interactions with large surface areas are very difficult to address with small molecules, and macrocycles are a very effective way of getting to a size that allows enough interaction with the protein."
A similar approach is to create constrained peptides by artificially linking linear peptides into specific structures possessing improved drug-like properties including cell permeability.
Ensemble is one of at least 12 biotechs developing platforms for synthesizing or screening macrocycles and constrained peptides (see "Building Cycles," A8).
As a group, these companies are enjoying a rush of attention from big pharma - there have been at least 27 discovery partnerships with biopharma partners in the last five years (see "Cycle Shops," A12).
"There is no doubt that within the last 3-4 years it has been a lot easier to get pharma's attention from a collaboration standpoint," said Tranzyme Inc. VP of IP and operations Mark Peterson. Tranzyme partnered its macrocycle discovery platform with Bristol-Myers Squibb Co. in 2009.
Indeed, collaboration looks to be essential to solving the puzzle of cell access. At this point, all the lead programs disclosed thus far are aiming at extracellular targets.
Not that I'm not agreeing with you my timeframe was just a little bit more than yours.
What makes you say that? I'm surprised if that's the case the stock hasn't moved up yet!
What is your timeframe?
the question is why would a company pour 80 million into a company with a market cap of under 11million if they didn't think it was worth 10 time that? think about it that way.... at 27 million shares leaves you with a share price of $2.96 if they used that 80 million to just buy them out... plus think of it this way Tranzyme already paid off there 21 million in debt and have 21 million in cash on the books so if I was to buy you out for 80 million did it really cause me 80 million answer no cause I get the 21 million in the bank so it cost me 59 million in theory....
so sound to me that BMY thinks TRANZYME is worth a lot more then the current stock price tells us.....
the question is why would a company pour 80 million into a company with a market cap of under 11million if they didn't think it was worth 10 time that? think about it that way.... at 27 million shares leaves you with a share price of $2.96 if they used that 80 million to just buy them out... plus think of it this way Tranzyme already paid off there 21 million in debt and have 21 million in cash on the books so if I was to buy you out for 80 million did it really cause me 80 million answer no cause I get the 21 million in the bank so it cost me 59 million in theory....
so sound to me that BMY thinks TRANZYME is worth a lot more then the current stock price tells us.....
the question is why would a company pour 80 million into a company with a market cap of under 11million if they didn't think it was worth 10 time that? think about it that way.... at 27 million shares leaves you with a share price of $2.96 if they used that 80 million to just buy them out... plus think of it this way Tranzyme already paid off there 21 million in debt and have 21 million in cash on the books so if I was to buy you out for 80 million did it really cause me 80 million answer no cause I get the 21 million in the bank so it cost me 59 million in theory....
so sound to me that BMY thinks TRANZYME is worth a lot more then the current stock price tells us.....
The company's pipeline is comprised of two preclinical stage compounds, TZP-201, a motilin agonist for chemotherapy-induced diarrhea, and TZP-301, a ghrelin antagonist for the treatment of metabolic diseases. Tranzyme's product candidates were discovered using its proprietary chemistry technology platform, MATCH™, which enables the construction of synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient manner. MATCH™ is a proven technology capable of finding candidate macrocycle molecules independent of target type or disease area. It is this technology that makes Tranzyme an interesting play here. In January they announced the successful completion of a chemistry-based drug discovery collaboration with Bristol-Myers Squibb (BMY). As a result of the joint research efforts, Tranzyme transferred compounds to Bristol-Myers Squibb for further development across multiple drug targets. Bristol-Myers Squibb is responsible for completing preclinical and clinical development of all products arising from the collaboration, and for their commercialization globally. Total milestone payments under the agreement, excluding royalties and sales milestones, could reach up to approximately $80 million for each target program. This could prove to be a very lucrative deal for Tranzyme in the coming months and years as new drugs are developed. Each new drug could be worth up to $80m and Tranzyme does not have to spend a dime of its cash developing!
They will just sit tight this stock is a jackpot all in time!
TZYM going to MOVE big from here!
Buying is on ready to pop any day now!
Orphan Drugs must read to all the longs!
Orphan Drugs: 'Rare' Opportunities To Make Money
An estimated 25 million people in the US alone collectively live with some sort of orphan disease. Despite the understanding that specific diseases may afflict relatively small numbers of individuals, this overall growing pool of patients is now becoming an attractive opportunity for the pharmaceutical industry. This reflects the fact that appropriate treatments for unmet medical needs that generate high levels of reimbursement.
“The high cost of therapy and attractive developmental drivers, such as government incentives (including tax credits), smaller and shorter clinical trials, extended exclusivity and high rates of regulatory success, have made top orphan drugs as equally viable as their non-orphan peers,” according to a new report from Thomson Reuters, which found the orphan drug market was worth slightly more than $50 billion worldwide at the end of last year.
Meanwhile, spending on orphan drugs currently makes up approximately 6 percent of total pharmaceutical sales, assumint a total market value of $880 billion. The compound annual growth rate of the orphan drug market between 2001 and 2010 was 25.8 percent, compared with 20.1 percent for a matched control group of non-orphan drugs. Combined with the increasing number of orphan drug approvals, the data suggests compounded annual growth will outpace other drugs.
Higher prices underscore the potential. In 2010, the most expensive drug was Soliris, which costs more than $409,000 annually and is used to treat paroxysymal nocturnal hemoglobinuria, a rare life-threatening blood disease. The med generated $541 million in sales for Alexion Pharmaceuticals. “This is a considerable achievement in terms of revenue, considering only 4,000 to 6,000 people suffer from this disease in the US,” the report states.
Moreover, repositioning such drugs to tre Less
Nice to see
Japan-based drug manufacturer Takeda Pharmaceutical is to acquire the US pharmaceutical firm URL Pharma for an upfront payment of $800m
Japan-based drug manufacturer Takeda Pharmaceutical is to acquire the US pharmaceutical firm URL Pharma for an upfront payment of $800m.
The gout treatment manufacturer has achieved relative success with its lead product Colcrys, used to treat flare-ups of gout, which recorded revenue in excess of $430m in 2011.
Takeda is Japan's largest pharmaceutical company, but is threatened by the patent expiry of its diabetes treatment Actos which occurs later this year. Although the company still possesses other medications, Takeda is thought to be seeking additions to its portfolio in able to offset expected losses.
Takeda has noted that it expects the acquisition to "contribute significantly" to the company's revenues, operating income and free cash flow as of 2013.
Takeda already has a foothold in the gout treatment market with its drug Uloric, used to lower blood uric levels in adults suffering from gout.
Takeda Pharmaceuticals USA president Douglas Cole said the company was pleased to add URL's Colcrys to its product portfolio, with the company now in a position to offer multiple treatment options for the disease.
"This acquisition expands Takeda's gout treatment portfolio and leverages our expertise in primary care," added Cole.
The acquisition is expected to close within 60 days subject to customary closing conditions, and URL's current owners may also be eligible to receive future performance-based payments as of 2015. Less
Huge buying going on ......... http://yahoo.brand.edgar-online.com/default.aspx?cik=722104
Krystexxa could well end up to be the Viagra of Savient. It may possibly even be better? Competitors in the gout treatment arena work by lowering the amount of Uric acid as a percent. They still allow unacceptable amounts of uric acid to pass through the Kidneys, though not as much. That is small consolation because every drop of uric acid that flows through an already compromised kidney is one step closer to dialysis.
It turns out that if you can delay or improve the prospects for someone suffering from Kidney disease, and limit their need for dialysis you can save the healthcare system gobs of money. To say billions worldwide is not hyperbolic.
Based upon conservative assumptions for the size of the refractory gout population (50-60K patients), penetration (12% in 2015), and duration of therapy (3 or 12 months depending on patient’s response), they estimate U.S. sales of $300MM.
8.0 million people in the US with gout and the market is growing at 3% to 5% per year.
Despite numerous setbacks and poor execution, Savient still has a strong product soon to see a favorable situation.. Let's not forget big pharma is still out there, desperately looking for (revenue) acquisition candidates. Savient still fits the bill.
Total Shares Held: 80 41,408,696 New Positions: 15 1,729,844 Increased Positions: 26 2,706,756 Decreased Positions: 41 3,536,233 Holders With Activity: 67 6,242,989 Sold Out Positions: 20 1,327,525
Read more: http://www.nasdaq.com/symbol/svnt/institutional-holdings#ixzz2MEpproCT http://www.nasdaq.com/symbol/svnt/institutional-holdings
That sure makes a lot of sense thanks!
where do you think this could be headed?
Calm before the storm!
I just bought..
This was all orchestrated get the shorts to get squeezed it sucks to be on the wrong side of the trade see you all at $2 plus soon!
With that considering DARA could be a nice five bagger!